Molbio Diagnostics joined the Unicorn Club on Sep 23, 2022 after reaching a $1.6 billion valuation. Headquartered in Salcete, Goa, India, Molbio Diagnostics develops point-of-care molecular diagnostic platforms for infectious disease detection.
The platform includes Trueprep, a fully automatic universal cartridge-based sample prep device; Prolab Atlus, a portable x-ray system; Thermalytix, an AI-based thermal scanning device; and Truelab, a real-time quantitative micro-PCR analyzer. These solutions target diseases including rifampicin resistance, COVID‑19, influenza, dengue, hepatitis, HPV, malaria, and others.
Keep reading to learn how Molbio Diagnostics became a $1.6 billion leader in genomics and infectious disease diagnostics.
What Is Molbio Diagnostics and What Does It Do?
Founded in 2000, Molbio Diagnostics provides molecular diagnostic solutions for rapid and accurate infectious disease detection. The platform enables real-time testing, AI-assisted thermal scanning, and portable diagnostics for point-of-care applications.
Molbio Diagnostics focuses on improving access to diagnostics, enhancing disease detection accuracy, and providing scalable laboratory and field-deployable solutions for healthcare providers worldwide.
How Much Funding Has Molbio Diagnostics Raised?
1. Series C Round
- Amount Raised: ~$124 million
- Date: 2022
- Key Investors: Temasek, Motilal Oswal Private Equity
- Purpose: Expand diagnostic platform, scale operations, and enhance molecular testing solutions
Total Funding Raised: $124 million Latest Funding Date: 2023 Latest Known Valuation: $1.6 billion Employee Count: 714
Key Investors
- Temasek
- Details: Global investment company investing in innovative healthcare and technology companies
- Focus Areas: Life sciences, genomics, healthcare platforms, and diagnostics
- Motilal Oswal Private Equity
- Details: Private equity firm investing in high-growth Indian companies
- Focus Areas: Healthcare, diagnostics, and biotechnology solutions
Where Is Molbio Diagnostics’ Headquarters?
Molbio Diagnostics is headquartered in Salcete, Goa, India, serving as the hub for R&D, manufacturing, and deployment of molecular diagnostic solutions.
What’s Next for Molbio Diagnostics?
Molbio Diagnostics plans to expand point-of-care diagnostic solutions, enhance AI-based screening technologies, and grow adoption of its molecular diagnostic platforms across hospitals, labs, and healthcare facilities globally.
Get Investor and Funding Insights with TexAu
TexAu provides verified investor and funding intelligence for companies like Molbio Diagnostics. Explore insights on genomics, infectious disease diagnostics, and high-growth healthcare technology startups.
Sign up for Free to access real time investor and funding intelligence.